In a recent meta-analysis of the literature, tamoxifen use for the treatment of a first breast cancer resulted in a significant 44% risk reduction of a second breast cancer in both BRCA1 and BRCA2 mutation-positive patients combined (summary HR = 0.56; 95% CI 0.41–0.76) [87]. The gene discussed is BRCA2; the disease is breast cancer.